학술논문

A 72-Week Randomized Study of the Safety and Efficacy of a Stavudine to Zidovudine Switch at 24 Weeks Compared to Zidovudine or Tenofovir Disoproxil Fumarate when Given with Lamivudine and Nevirapine
Document Type
article
Source
Antiviral Therapy. 17(8)
Subject
Clinical Research
Infectious Diseases
Clinical Trials and Supportive Activities
HIV/AIDS
Prevention
Evaluation of treatments and therapeutic interventions
6.1 Pharmaceuticals
Adenine
Adult
Antiretroviral Therapy
Highly Active
CD4 Lymphocyte Count
Diet
Drug Administration Schedule
Drug Substitution
Female
Glomerular Filtration Rate
HIV Infections
Hemoglobins
Humans
Lamivudine
Male
Nevirapine
Organophosphonates
Peripheral Nervous System Diseases
Stavudine
Tenofovir
Treatment Outcome
Viral Load
Zidovudine
SEARCH 003 Study Group
Microbiology
Clinical Sciences
Medical Microbiology
Virology
Language
Abstract
BackgroundDue to superior long-term toxicity profiles, zidovudine (AZT) and tenofovir disoproxil fumarate (TDF) are preferred over stavudine (d4T) for first-line antiretroviral regimens. However, short-term d4T use could be beneficial in avoiding AZT-induced anaemia.MethodsWe randomized (1:1:1) 150 treatment-naive Thai HIV-infected adults with CD4(+) T-cell count